Expanding New Treatment Option to Frontline Treatment for Hodgkin Lymphoma

Dr. Steven Park from the UNC Lineberger Comprehensive Cancer Center, explains trials for the use of brentuximab vedotin (Adcetris) in the frontline setting for Hodgkin lymphoma. Dr. Park explains how this antibody drug conjugate is being tested against drug treatments like ABVD and how it may help patients avoid radiation treatment that can be harmful down the road.